An initial test had high specificity for AQP4-antibody disease.
Aquaporin-4 antibodies (AQP4 Abs) have been noted by some groups to occasionally be initially negative and to fluctuate. AQP4 Ab has been proposed as a biomarker of treatment response and impending relapse. Investigators retrospectively evaluated AQP4 serum tests in 933 patients who had at least 2 test results and an initial positive result.
Of the 933 patients, 11% seroreverted to negative at a median of 1.2 years, more commonly in patients ≤20 years old and with low initial titers. For those with positive titers, AQP4 was stable in 92%. Of those retested after seroreversion, 50% returned to seropositive. Of 9308 patients with an initial negative test, 99% remained seronegative and 0.3 seroconverted to positive a median of 0.9 years after t…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)